Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 STA, TESARO Ink Five-Year Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

STA, TESARO Ink Five-Year Supply Pact

STA will provide certain starting and intermediate materials for the recently launched ZEJULA

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

STA Pharmaceutical Co., Ltd., a WuXi AppTec subsidiary, has signed a supply agreement with the oncology-focused biopharmaceutical company, TESARO, Inc. for certain starting and intermediate materials for ZEJULA (Niraparib).

 

Under the five-year agreement, STA will provide certain starting and intermediate materials for the recently launched ZEJULA – an orally active and potent poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of ovarian cancer. ZEJULA was FDA-approved for epithelial ovarian, fallopian tube or primary peritoneal cancer on March 27th 2017, and is now available to patients in the U.S. This agreement follows a successful multiple-year development and clinical manufacturing arrangement with TESARO.

 

A Phase III trial demonstrated that ZEJULA offers a clinically meaningful increase in progression-free survival (PFS) in women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status.

 

“We have been working with TESARO for a number of years, and we are honoured to be selected as a TESARO global supplies partner for this critical life-saving drug,” said Dr. Minzhang Chen, chief executive officer of STA Pharmaceutical. “STA is committed to helping our partners develop and commercialize innovative breakthrough drugs like ZEJULA via our state-of-the-art enabling platform. It has been an extremely successful partnership and we look forward to working alongside the TESARO team to expedite their development and commercial timelines.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics